Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
A new study led by Princess Margaret (PM) Cancer Centre Research Director Dr. Aaron Schimmer suggests that an increase in a certain class of fats, known as phospholipids, plays a fundamental role in the initiation and growth of acute myeloid leukemia (AML) – an aggressive form of blood cancer.
Phospholipids have many important roles in the body, including storing energy, relaying messages and serving as the building blocks of life. Because of this, changes in these fat-like substances are linked to a number of diseases, including cancer.
Dr. Schimmer and his team found that loss of a protein known as Taffazin (TAZ) increased levels of the phospholipid phosphatidylserine and decreased the growth and survival of specific AML cells that are known to initiate and maintain disease. Interestingly, their experiments showed that loss of TAZ had no effects on healthy blood cells.
"These findings shed new light on the impact that phospholipids have on leukemia initiation and progression," says Dr. Schimmer. "Finding ways to change the composition of these molecules in the body may represent a new way to block the development or progression of AML."
This work was supported by the Canadian Institutes of Health Research, the Ontario Institute for Cancer Research, the Government of Ontario, the National Institutes of Health, the University of Toronto, the PM Cancer Centre, the Lady Tata Memorial Trust and The Princess Margaret Cancer Foundation. Dr. Schimmer holds the Barbara Baker Chair in Leukemia and Related Diseases.